Whether or not a new class of botanical-- or “polymolecular”-- drugs will have cost benefits over synthetic or biotechnology products, Dr. 霍夫曼还认为美国食品和药物管理局的这一决定将会对处理正在激烈进行的争论起关键的作用。
Freddie Ann Hoffman, MD, an expert on this botanical drug process, said, “A new drug industry has just been born -- perhaps ‘reborn’ -- in the United States: the polymolecular botanical drug industry. 植物药物方面的专家，医学博士弗雷迪.;安
